Literature DB >> 16917430

Critical care of immunocompromised patients: human immunodeficiency virus.

Mark J Rosen1, Mangala Narasimhan.   

Abstract

OBJECTIVE: To describe critical illnesses that occur commonly in patients with human immunodeficiency virus (HIV) infection.
METHODS: We reviewed and summarized the literature on critical illness in HIV infection using a computerized MEDLINE search.
SUMMARY: In the last 10 yrs, our perception of HIV infection and acquired immune deficiency syndrome (AIDS) has changed from an almost uniformly fatal disease into a manageable chronic illness. Even patients with advanced immunosuppression may have prolonged survival, although usually with exacerbations and remissions, complicated by therapy-related toxicity and medical and psychiatric co-morbidity. The prevalence of opportunistic infections and the mortality have decreased considerably since early in the epidemic. The most common reason for intensive care unit admission in patients with AIDS is respiratory failure, but they are less likely to be admitted for Pneumocystis pneumonia and other HIV-associated opportunistic infections. HIV-infected persons are more likely to receive intensive care unit care for complications of end-stage liver disease and sepsis. Hepatitis C has emerged as a common cause of morbidity and mortality in patients with HIV infection. In addition, some develop life-threatening complications from antiretroviral drug toxicity and the immune reconstitution inflammatory syndrome.

Entities:  

Mesh:

Year:  2006        PMID: 16917430     DOI: 10.1097/01.CCM.0000232491.15369.AB

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  8 in total

1.  Molecular diagnostics for invasive fungal infections: a call for refinement and implementation.

Authors:  Gary W Procop
Journal:  J Mol Diagn       Date:  2009-12-10       Impact factor: 5.568

2.  Pulmonary infections in the HIV-infected patient in the era of highly active antiretroviral therapy: an update.

Authors:  Deepa G Lazarous; Anne E O'Donnell
Journal:  Curr Infect Dis Rep       Date:  2007-05       Impact factor: 3.725

3.  Survival trends in critically ill HIV-infected patients in the highly active antiretroviral therapy era.

Authors:  Isaline Coquet; Juliette Pavie; Pierre Palmer; François Barbier; Stéphane Legriel; Julien Mayaux; Jean Michel Molina; Benoît Schlemmer; Elie Azoulay
Journal:  Crit Care       Date:  2010-06-09       Impact factor: 9.097

4.  Sepsis is a major determinant of outcome in critically ill HIV/AIDS patients.

Authors:  André M Japiassú; Rodrigo T Amâncio; Emerson C Mesquita; Denise M Medeiros; Helena B Bernal; Estevão P Nunes; Paula M Luz; Beatriz Grinsztejn; Fernando A Bozza
Journal:  Crit Care       Date:  2010-08-10       Impact factor: 9.097

5.  Investigations into the physical and chemical stability of concentrated co-trimoxazole intravenous infusions.

Authors:  Israa Khaleel; Syed Tabish R Zaidi; Madhur D Shastri; Mathew Suji Eapen; Long Chiau Ming; Troy Wanandy; Rahul P Patel
Journal:  Eur J Hosp Pharm       Date:  2017-07-19

6.  Admissions to intensive care unit of HIV-infected patients in the era of highly active antiretroviral therapy: etiology and prognostic factors.

Authors:  Hou-Hsien Chiang; Chien-Ching Hung; Chang-Min Lee; Hsuan-Yu Chen; Mao-Yuan Chen; Wang-Huei Sheng; Szu-Min Hsieh; Hsin-Yun Sun; Chao-Chi Ho; Chong-Jen Yu
Journal:  Crit Care       Date:  2011-08-26       Impact factor: 9.097

7.  Etiology and Outcome of Patients with HIV Infection and Respiratory Failure Admitted to the Intensive Care Unit.

Authors:  Jose Orsini; Noeen Ahmad; Ashvin Butala; Rosemarie Flores; Truc Tran; Alfonso Llosa; Edward Fishkin
Journal:  Interdiscip Perspect Infect Dis       Date:  2013-08-28

8.  Etiologies and outcome of acute respiratory failure in HIV-infected patients.

Authors:  François Barbier; Isaline Coquet; Stéphane Legriel; Juliette Pavie; Michael Darmon; Julien Mayaux; Jean-Michel Molina; Benoît Schlemmer; Elie Azoulay
Journal:  Intensive Care Med       Date:  2009-07-03       Impact factor: 17.440

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.